BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Mirati Therapeutics Reports Third Quarter 2017 Financial Results

  Cash, cash equivalents, and short-term investments were $75M at September 30, 2017, compared to $56.7M at December 31, 2016.

  November 1, 2017

   · 

  10 min read
• Drug Development

  United Neuroscience Presents Data for Phase II Active Vaccine Program UB-311 at the Clinical Trials on Alzheimer’s Disease 2017 Meeting

  The data showed that UB-311 was able to generate antibodies to specific Ab oligomers and fibrils with no decrease in antibody levels in patients of advanced age.

  November 1, 2017

   · 

  3 min read
• Business

  vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results

  vTv Therapeutics provided a corporate update and reported financial and operational results for the third quarter ended September 30, 2017.

  November 1, 2017

   · 

  11 min read
• BioMidwest

  Bristol-Myers Squibb recognizes JLL for Service Delivery Excellence

  JLL has been recognized by global biopharmaceutical company Bristol-Myers Squibb with a Service Delivery Excellence Award announced at the company’s annual Global Suppliers Conference.

  November 1, 2017

   · 

  1 min read
• Business

  Astellas Announces Leadership Changes in U.S. Health Systems Commercial Organization

  Astellas today announced two senior-level changes in its U.S. Commercial organization within the company’s Health Systems business unit.

  November 1, 2017

   · 

  2 min read
• Business

  AtriCure Reports Third Quarter 2017 Financial Results

  Revenue for the third quarter of 2017 was $42.2 million, an increase of $3.8 million or 9.9% (9.3% on a constant currency basis), compared to third quarter 2016 revenue.

  November 1, 2017

   · 

  11 min read
• Business

  Foundation Medicine Announces 2017 Third Quarter Results and Recent Highlights

  Foundation Medicine reported total revenue of $42.7 million in the third quarter of 2017, compared to $29.4 million in the third quarter of 2016.

  November 1, 2017

   · 

  9 min read
• BioForest

  Seattle Genetics to Present Data From Broad ADCETRIS (Brentuximab Vedotin) Development Program at ASH 2017

  Seattle Genetics today announced that 18 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin) development program have been accepted for presentation.

  November 1, 2017

   · 

  16 min read
• Results of TherOx AMI Study for Improved Patient Outcomes Meets Primary Endpoint

  These results are included in the PMA application for the SSO2 Therapy system that has been accepted for filing by FDA

  November 1, 2017

   · 

  3 min read
• Drug Development

  Atara Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results From a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus-Associated Cancers

  The Company’s collaborating investigators at Memorial Sloan Kettering Cancer Center will present, on behalf of eight major transplant centers in the U.S.

  November 1, 2017

   · 

  12 min read